Virulite seeks suitor, FDA approval for new cold sore remedy
COSTA MESA, Calif. Virulite, a medical device manufacturer developing a new treatment for cold sores, is looking for a U.S. suitor, having retained Compass Point Capital and Murphy Business and Financial Corporation as its mergers and acquisitions advisors, the U.K. company announced Friday.
Virulite is presently in the process of obtaining Food and Drug Administration clearance for a portable, hand held device that uses an invisible, non-thermal band of near-infrared light that, according to the company, reduces the healing time of cold cores by up to one half.
The company completed a U.S. market test of the product through Walgreens’ online distribution channel, where Virulite outsold all competing cold sore remedies, including the current market leader, the topical cream Abreva by GlaxoSmithKline, Virulite reported.
Merz announces distribution of Mederma scar management w/sun protection
GREENSBORO, N.C. Merz Pharmaceuticals will begin distributing its Mederma Cream + SPF 30, which helps reduce the appearance of scars while protecting them from the sun, in March, the company announced Friday.
“In nationwide discussions with consumers who are affected by scars, we identified an unmet need in the marketplace for a better scar management product which offers the sun protection that consumers expect,” stated Javier Perez, product manager for Mederma.
New scars are susceptible to becoming discolored by the sun, the company noted, citing dermatologist to minimize sun exposure to new scars.
Study pinpoints best aspirin dosage for heart attack victims
DALLAS While many consumers at risk of heart disease supplement with 81 mg of aspirin daily, a recent study published in this week’s edition of the American Heart Association journal Circulation found that double that dose significantly reduces mortality in people who are suffering from a heart attack.
The International Study of Infarct Survival trial demonstrated that treatment with 162.5 mg aspirin reduces morbidity and mortality in heart attack patients, at least as much as 325 mg of aspirin, but is not associated with a significant increase in risk of moderate or severe bleeding as is the case with the higher dose of aspirin.
Presently, the most common initial dose of aspirin in the immediate aftermath of a heart attack is 325 mg.
On the basis of these data, the American College of Cardiology, American Heart Association and European Society of Cardiology gave a class I level of evidence A to immediate use of 162 mg of aspirin, which is the strongest recommendation backed by strong evidence of efficacy as ranked by the organizations.
“Although these data are non-randomized, they suggest that for the first dose of aspirin, 162 mg may be as effective as and safer than 325 mg for the acute treatment of [a heart attack],” the study concluded.